Health Care

Hyperliquid launches a Washington, D.C. policy center to shape U.S. DeFi and perpetual derivative rules, positioning itself as a crypto‑policy influencer.

Rubicon Organics opens its Cascadia facility, boosting specialty cannabis and organic pharma production while showing a low‑PE, undervalued stock poised for growth.

Capricor Therapeutics, a clinical‑stage biotech focused on Duchenne muscular dystrophy, drew a high‑profile stake from Tang Capital, boosting investor confidence and highlighting its promising yet volatile stock prospects.

QIAGEN NV boosts its single‑cell genomics lineup with Parse Biosciences Evercode V4, expands into Japan’s point‑of‑care market, and navigates industry consolidation while maintaining stable equity performance.

Discover how Traws Pharma’s Phase‑2 COVID‑19 study milestone fuels its promising cancer‑drug pipeline, market insights, and investor outlook.

Stevanato Group SpA’s glass packaging expertise fuels its $4.36B market cap and strong NYSE performance, driving growth for global pharma supply chains.

Northwest Biotherapeutics

HealWELL AI’s breakthrough in AI‑powered primary care sparks investor interest—yet negative earnings and a 52‑week volatility chart reveal the risks of this fast‑growing digital health tech firm.

Dexcom’s recent earnings miss spiked a sharp share‑price drop, but long‑term CGM growth and historic returns hint the stock may still be undervalued and worth watching.

Phio Pharmaceuticals, a biotech firm focused on cancer immunotherapy, showcased at 2026 DealFlow Discovery and faces volatile stock yet promising asset value.